A recent study conducted by experts based at University of Nottingham in the UK has revealed that young individuals afflicted by certain kinds of cancer like bone malignancies take longer before being diagnosed.
Cancer among children is now regarded to be a worldwide disease burden, and getting an early diagnosis has been made a priority. The researchers undertook their study in order to enable the broader research community to get an understanding of what kids and young people go through starting with the onset of symptoms to the point at which a cancer diagnosis is made.
To this end, the team obtained data on 1,957 young people not exceeding 18 years of age who had a cancer diagnosis made in the years 2020 to 2023 in the United Kingdom. The study was led by Doctor Shaarna Shanmugavadivel, Prof. David Walker and Prof. Shalini Ojha. The trio works at the University of Nottingham at the School of Medicine.
Commenting about their findings, Doctor Shanmugavadivel revealed that the team had obtained a clear understanding of the country’s current cancer diagnosis landscape for young adults and children. He added that it is worth celebrating that their findings indicated that the time needed to obtain a cancer diagnosis in this demographic isn’t impacted by sex, ethnicity or socioeconomic factors.
However, Shanmugavadivel drew attention to the fact that more attention needs to be directed towards addressing the factors making certain types of malignancies, such as bone cancers, to take longer to be diagnosed in this demographic. He pointed out that timely diagnosis is crucial since tumors can proliferate rapidly and delays in diagnosis can cost lives or necessitate extensive surgical procedures or aggressive therapies which would have been avoided if the cancer had been identified earlier.
The researchers found that teenagers aged between 15 and 18 years required an average of 8.7 weeks to obtain a diagnosis. This was the longest span found during the research. Infants who hadn’t reached a year of age had the shortest duration prior to diagnosis, clocking in at an average of 3.7 weeks.
In terms of tumor types, bone cancers exhibited the longest average interval before a diagnosis was made (12.6 weeks) while kidney malignancies were diagnosed fastest in an average of 2.3 weeks.
The study also discovered that in nearly 8 out of 10 cases, the subjects required 1-3 hospital visits before being diagnosed with the cancer affecting them. Brain cancers, soft tissue cancers and bone cancers often required more hospital visits before a diagnosis could be made.
The team hopes that their findings will help in designing interventions to reduce the duration before diagnosis in the cases that exhibited the longer times prior to a diagnosis being made. As these efforts to reduce the time before a diagnosis is made get underway, other parallel efforts by companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to develop more efficacious treatments for pediatric central nervous system cancers and brain tumors in general, are also taking place to improve patient outcomes.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
